All In Biotech

Drug Trial Radar · NCT06877247

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Dec 23, 2024

Primary completion

Apr 4, 2025

Study completion Oct 11, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] SHR6508.

Conditions

  • Secondary Hyperparathyroidism

Interventions

  • [14C] SHR6508 InjectionDrug

    \[14C\] SHR6508 injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative excretion of radioactivityTime frame: Day 1 to Day 168.
  2. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)Time frame: Day 1 to Day 6.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.